Zafirlukast

Research use only, not for human use.

A potent, selective, orally active leukotriene D4 (LTD4) receptor antagonist antagonist for the maintenance treatment of asthma.

A potent, selective, orally active leukotriene D4 (LTD4) receptor antagonist antagonist for the maintenance treatment of asthma.Asthma Approved(In Vitro):Zafirlukast is a peptidyl leukotriene antagonist and inhibitor of LTD4. After 13 weeks of exposure, the yield of lung tumors is significantly decreased by both dose levels of Zafirlukast (270 and 540 mg/kg), the high dose of Zileuton (1200 mg/kg), and the combinations containing 600 mg/kg Zileuton with either Zafirlukast or MK-866. The efficacy of the combination containing Zileuton and Zafirlukast to prevent lung tumors is not significantly different from the efficacy of either inhibitor administered alone. Although when administered alone at the dose level in their combination, neither Zileuton or MK-886 prevents lung tumors; the combination containing them does significantly prevent tumors. In contrast, the combination containing Zafirlukast and MK-886 does not reduce the yield of tumors, whereas Zafirlukast administered alone does significantly reduce the yield of tumors.

——

——

ICI-204219

GPCR/G Protein

Leukotriene Receptor

leukotrienereceptor

Inflammation/Immunology

Asthma

107753-78-6

575.6752

C31H33N3O6S

>98% (HPLC)

10 mM in DMSO

O=C(OC1CCCC1)NC2=CC3=C(N(C)C=C3CC4=CC=C(C(NS(=O)(C5=CC=CC=C5C)=O)=O)C=C4OC)C=C2

Carbamic acid, N-[3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]-, cyclopentyl ester

(-20℃)

With Ice Pack

≥ 2 years